HCA Healthcare
Key Metrics
How this company measures up on the fundamentals that matter
About HCA Healthcare
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $435 against a fair value of $663, a 34% discount. Fails ethical screen (Debt ratio). Ranks better than 68% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | MARKS MIKE A | Chief Financial Officer | 3,336 | — | |
| 2026-04-28 | MICHELSON MICHAEL W | Director | 925 | — | |
| 2026-04-28 | CHIDSEY JOHN W | Director | 809 | — | |
| 2026-04-28 | DEPARLE NANCY-ANN M. J.D. | Director | 509 | — | |
| 2026-04-28 | RILEY WAYNE JOSEPH | Director | 509 | — | |
| 2026-04-28 | FRIST THOMAS F III | Director and Beneficial Owner of more than 10% of a Class of Security | 1,041 | — | |
| 2026-04-28 | JOHNSTON HUGH F. | Director | 809 | — | |
| 2026-04-28 | SMITH ANDREA B | Director | 509 | — | |
| 2026-04-28 | FRIST WILLIAM R. | Director and Beneficial Owner of more than 10% of a Class of Security | 809 | — | |
| 2026-02-18 | MCALEVEY MICHAEL R. | Officer | 1,694 | $903,537 |
Political Trading Activity
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-20 | Jonathan Jackson | Democrat | Sale | 15K–50K |
| 2026-04-15 | Jonathan Jackson | Democrat | Sale | 1K–15K |
| 20 Apr2026 | Jonathan Jackson | Democrat | sell | 15K–50K |
| 15 May2026 | Ro Khanna | Democrat | sell | 1K–15K |
| 15 Apr2026 | Jonathan Jackson | Democrat | sell | 1K–15K |
What If You'd Bought HCA?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $426.37 | -12.9% | — | $871 | -12.9% |
| 2 Months | $495.47 | -25.0% | — | $750 | -25.0% |
| 3 Months | $531.79 | -30.1% | $0.78 | $700 | -30.0% |
| 6 Months | $480.92 | -22.8% | $1.50 | $776 | -22.4% |
| 1 Year | $362.48 | +2.5% | $2.94 | $1,033 | +3.3% |
| 2 Years | $336.28 | +10.5% | $5.64 | $1,121 | +12.1% |
| 3 Years | $265.50 | +39.9% | $8.10 | $1,430 | +43.0% |
| 5 Years | $202.93 | +83.1% | $12.38 | $1,892 | +89.2% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Latest Analysis — HCA
Timestamped intelligence from our daily research pipeline
The Foundry · Complete Guides The Complete Guide to Reading the Jobs Report Titan Macro Desk • 4 July 2026 • 8 minute read Two days ago, US payrolls printed...
Eli Lilly (LLY) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height:...
AbbVie (ABBV) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height: 1.7;...
Pfizer (PFE) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height: 1.7;...
UnitedHealth Group (UNH) Case Study | Titan Protect * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', system-ui, -apple-system, sans-serif; line-height:...
Welltower (WELL) — Markup at $130.00 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container {...
Novartis (NVS) — Markup at $153.07 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container {...
Ligand Pharmaceuticals (LGND) — Markup at $255.54 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31